In addition, participants who took SGLT2 inhibitors at baseline (Supplementary Table 2) and participants with CKD (eGFR <60 mL/min/1.73 cm2) at baseline (Supplementary Table 3) were also excluded from the analysis. This evidence concerns the gene SLC5A2 and chronic kidney disease.